HLA-A2 HPV16 E7 Antigen-Binding Proteins for Targeted Cervical Cancer Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cervical cancer caused by human papillomavirus (HPV) are invasive and ineffective for advanced or recurrent cases, highlighting the need for new therapeutic strategies that can specifically target HPV.

Innovation Solution

Development of antigen-binding proteins that specifically bind to a conformational epitope of an HLA-displayed HPV 16 E7 peptide, allowing for targeted therapy and diagnosis of HPV-related diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional treatments (surgery, radiotherapy, chemotherapy) are used for cervical cancer, then early stage cancer may be treated, but the treatments are highly invasive and morbid with limited value for advanced or recurrent cancer

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidinvasiveness and morbidity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses HLA-A2:HPV16E7 antigen-binding proteins as intermediaries that specifically recognize and bind to cervical cancer cells expressing HPV16 E7 peptide. These proteins serve as mediators between the immune system and cancer cells, enabling targeted therapy that spares healthy tissues while effectively treating both early and advanced stage cancers without the invasiveness of traditional treatments

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the therapeutic parameter from non-specific cytotoxic effects of traditional treatments to highly specific antigen-antibody binding interactions. By targeting the specific HLA-A2:HPV16E7 complex, the treatment achieves cancer cell specificity based on molecular parameter recognition rather than broad tissue damage, reducing invasiveness while maintaining or improving effectiveness

Inventive Principle:

Principle #35Parameter changes

2Reliability

If vaccines targeting HPV L1 and L2 capsid proteins are used, then prevention of infection is achieved, but treatment of subjects with established lesions is not possible

Engineering Contradiction:

Improveprevention effectivenessVSAvoidtherapeutic applicability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The HLA-A2:HPV16E7 antigen-binding proteins serve multiple functions: they can prevent infection by blocking viral entry, treat established lesions by targeting infected cells, and provide diagnostic capability through specific binding. This multi-functionality allows the same therapeutic agent to address the full spectrum of HPV disease progression, from prevention to treatment of advanced lesions

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

Instead of targeting the viral capsid proteins (L1/L2) as vaccines do, this invention inverts the approach by targeting the host-virus complex (HLA-A2 presenting HPV16E7 peptide) on the surface of infected cells. This inversion enables therapeutic intervention in established infections where viral proteins are already expressed and presented, making treatment possible where prevention alone was insufficient

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20250064913A1Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

Publication Date: 2025.02.27 REGENERON PHARMACEUTICALS INC

AI summary

The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.